Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 77, Issue 9, Pages 1197-1207
Publisher
Elsevier BV
Online
2021-03-02
DOI
10.1016/j.jacc.2020.12.053
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis
- (2020) V. Mai et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared to Aspirin in Patients Chronic Vascular Disease
- (2020) Jan Steffel et al. CIRCULATION
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)
- (2020) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Direct Oral Anticoagulant Dosing
- (2020) Gerald V. Naccarelli JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants
- (2020) Alan John Camm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
- (2020) Ken Okumura et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
- (2019) Craig T. January et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
- (2019) M. S. Jacobs et al. Netherlands Heart Journal
- Impact of direct oral anticoagulants off‐label doses on clinical outcomes of atrial fibrillation patients: a systematic review
- (2019) Joana Santos et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Patients with Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial
- (2019) Frederik Dalgaard et al. CIRCULATION
- Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?
- (2018) Philippe Gabriel Steg et al. CIRCULATION
- Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial
- (2018) Ophelia Q. P. Yin et al. CIRCULATION
- Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
- (2018) Deirdre A. Lane et al. CLINICAL CARDIOLOGY
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
- (2018) Jan Steffel et al. EUROPEAN HEART JOURNAL
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- (2018) Gary E. Raskob et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
- (2017) Xiaoxi Yao et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
- (2016) Robert P. Giugliano et al. AMERICAN JOURNAL OF MEDICINE
- Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling
- (2016) Jan Steffel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes
- (2016) Benjamin A. Steinberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
- (2015) Christian T Ruff et al. LANCET
- Bleeding complications during anticoagulant treatment in patients with cancer
- (2014) Pieter W. Kamphuisen et al. THROMBOSIS RESEARCH
- The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
- (2013) Daniel E. Singer ANNALS OF INTERNAL MEDICINE
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
- (2012) Jeanne Mendell et al. THROMBOSIS AND HAEMOSTASIS
- Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
- (2011) B. Nhi Beasley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
- (2010) Christian T. Ruff et al. AMERICAN HEART JOURNAL
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now